what the studies administered
CJC-1295 dosage, as it appears in the research record
The doses, routes and handling documented in the published literature — described, not prescribed, because CJC-1295 has no approved human use.
CJC-1295 doses used in research
Human pharmacokinetic studies of CJC-1295 used single subcutaneous doses of 30, 60 or 90 micrograms per kilogram [2][3]. Teichman and colleagues dosed at 30 and 60 micrograms per kilogram; Ionescu and Frohman used 60 and 90 micrograms per kilogram in young men [2][3]. The animal growth study in GHRH-knockout mice used a fixed 2 micrograms per dose, given at 24-, 48- or 72-hour intervals, with the once-daily schedule proving most effective [4].
Those are the doses that exist in controlled work, and they are reported here as research doses — what was administered to which subjects by which route — not as guidance. CJC-1295 is not approved for human use, so there is no labeled dose to quote [9]. The fixed 100-300 microgram "protocols" that circulate online for no-DAC Modified GRF 1-29 and for CJC-1295/ipamorelin are not derived from controlled human trials [9].
CJC-1295 dosage anchored to the human PK studies
Every defensible CJC-1295 dosage figure traces back to the same two human pharmacokinetic studies: 30 and 60 micrograms per kilogram in Teichman 2006, and 60 and 90 micrograms per kilogram in Ionescu/Frohman 2006 [2][3]. Anything outside that 30-90 microgram-per-kilogram subcutaneous window is extrapolation, not data, and no dose has been validated for an outcome in healthy adults [9].
How much CJC-1295 should I take?
Human pharmacokinetic studies used single subcutaneous doses of 30, 60 or 90 micrograms per kilogram [2][3]. These are research doses, not a recommendation: they were chosen to characterize GH and IGF-1 kinetics, not to optimize any outcome, and CJC-1295 is not approved for human use [9]. No validated dose for any goal exists.
How to reconstitute CJC-1295?
In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated [9]. Oral bioavailability is negligible, so the routes studied are subcutaneous — the primary route — and intravenous in the earliest GRF(1-29) work [9]. This describes laboratory handling of a research compound, not a preparation instruction for human use.
Where to inject CJC-1295?
Subcutaneous injection is the primary route used across the CJC-1295 research literature; intravenous administration appears in early GRF(1-29) pharmacokinetic work [9]. The published studies report the route of administration rather than anatomical injection sites, and CJC-1295 has no approved human indication [9].
Routes and bioavailability
CJC-1295 is a peptide, so oral bioavailability is negligible — the molecule does not survive the gut [9]. The route studied is injection. Subcutaneous administration is the primary route across the human and animal literature; intravenous dosing appears in the earliest GRF(1-29) pharmacokinetic work [9].
The DAC variant's albumin conjugation does not change the route, only the duration: it is still injected subcutaneously, but a single dose acts for days rather than minutes because the albumin link slows clearance [1]. The no-DAC form is also injected but clears quickly, which is the entire practical difference between the two — covered in full on the half-life and pharmacokinetics page.
Handling and stability in the literature
As a research compound, CJC-1295 is supplied lyophilized — freeze-dried to a powder — and in research handling is reconstituted with bacteriostatic water and refrigerated [9]. The four amino-acid substitutions confer resistance to DPP-IV and other proteases; the DAC conjugation confers the multi-day duration of action [1][9].
The peptide's stability profile is part of why it was engineered the way it was: native GHRH is fragile, and CJC-1295's substitutions plus albumin binding were the design answer to that fragility [1]. None of this constitutes a preparation instruction for human use — it is a description of how the compound behaves on the laboratory bench, drawn from the published record.
Why the human dosing picture stays incomplete
The honest state of CJC-1295 dosing is that the only human numbers come from early pharmacokinetic studies, not from efficacy or safety trials [9]. Teichman 2006 and Ionescu/Frohman 2006 told us how a single subcutaneous dose moves GH and IGF-1 over days — they were not designed to find an optimal dose for any outcome, in any population, over any duration [2][3].
That is why this page describes a dose range rather than recommending one. The literature establishes that 30-90 micrograms per kilogram subcutaneously produces measurable, multi-day endocrine effects in healthy volunteers [2][3]. It does not establish what dose, if any, is appropriate for a person pursuing a goal — because no controlled trial has asked that question.